Alzheimer's, atherosclerosis, and aggregates: a role for bacterial degradation.
Several of the most prevalent and severe age-related diseases, notably Alzheimer's disease and atherosclerosis, feature the accumulation of non-degradable aggregates within the lysosomes of disease-affected cells. At an early point in disease progression, the breakdown of lysosomal contents by the resident catabolic enzymes stops working properly. A return of lysosomal enzymatic activity to pre-disease levels may restore aggregate elimination. In this review, a method of bioremediation-derived lysosomal enzyme enhancement is proposed, featuring the cellular introduction of microbial-isolated enzymes, or xenoenzymes. The benefits and challenges of using xenoenzymes to break down aggregates are discussed. As the size of our elderly population grows, the incidence of age-related diseases will increase, necessitating the exploration of radical, but potentially powerful, therapeutic strategies.
de Grey
Aubrey D
AD
Methuselah Foundation, Cambridge, United Kingdom. aubrey@sens.org
D000375:Aging / Q000187:drug effects / Q000473:pathology; D000544:Alzheimer Disease / Q000473:pathology / Q000628:therapy*; D050197:Atherosclerosis / Q000473:pathology / Q000628:therapy*; D001419:Bacteria / Q000201:enzymology; D006801:Humans; D016464:Lysosomal Storage Diseases / Q000628:therapy*; D008247:Lysosomes / Q000502:physiology*